This brand-new advocacy group is an unapologetic defender of high drug prices
It’s not clear who funds this new advocacy group or when it officially launched, but it’s already clear which side of the drug pricing debate it’s on.
WASHINGTON — It’s less than a week old, but a shadowy new pharma advocacy group is already launching diatribes against advocates for lower drug prices, blasting pharmacy middlemen and defending even sky-high list prices for prescription drugs.
